Meeting
2023 ASCO Annual Meeting
The value of progression-free survival at three years as a primary endpoint for studies on radiotherapy in patients with locally advanced cervical cancer: Individual patient data from Chinese National Cancer Center and validation from 27 global randomized trials.
Authors
Xi Yang
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Xi Yang , Jusheng An , Yuanyuan Zhang , Yong Yang , Shuangzheng Jia , Wei Li , Manni Huang , Lingying Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5534)
DOI
10.1200/JCO.2023.41.16_suppl.5534
Abstract #
5534
Poster Bd #
229
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Active bone marrow-sparing to reduce the incidence of grade 3+ acute hematologic toxicity in patients with locally advanced cervical cancer who receive chemoradiotherapy: A single-center prospective randomized controlled trial.
First Author: ShanBing Wang
Poster
2019 Gastrointestinal Cancers Symposium
Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.
First Author: Alicia Smart
Poster
2016 ASCO Annual Meeting
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study.
First Author: Milena Bruzzone
Poster
2016 ASCO Annual Meeting
Population-based assessment of disease free survival (DFS) as a surrogate endpoint (SE) of 5 year overall survival (5Y OS) in stage I-III rectal (RC) and colon cancer (CC).
First Author: Richard M. Lee-Ying